Latest News & Features

Reset all filters
Article Type
Channels & Sectors
Geography
Company
Refine Search
‘Loopholes’ in ITC orders? Blindsided Masimo takes aim at US customs
Americas
In a rare legal action, the medtech company claims the agency unlawfully let Apple reintroduce a feature on its watches that undermines an ITC ban.   21 August 2025
Invisalign maker sues Chinese rival in Europe, US, and China
Medtech
The $4 billion-a-year orthodontics company says its latest lawsuits defend “critical components” of its portfolio as rivals push cheaper alternatives.   21 August 2025
Overcoming refusal of TMs containing ingredient names in China
Asia
Hui Zhuang of CCPIT Patent and Trademark Law Office discusses several strategies to increase the chance of pharmaceutical or food trademarks that include ingredients being registered.   21 August 2025
Europe
The Japanese pharma company has defended a key patent for a treatment that achieved record 2024 sales of over $6 billion—but a patent cliff looms.   20 August 2025
Americas
In a New Jersey lawsuit, Henlius and Organon are accused of submitting an aBLA for a biosimilar that infringes two dozen patents.   19 August 2025
Americas
Several months after a US import ban sidelined a key Apple Watch feature, the tech giant is restoring a redesigned sensor to some models.   18 August 2025
Europe
Insulet and Masimo are among the parties that feature in this year’s one-of-a-kind rankings, courtesy of sister magazine WIPR, detailing the year’s most significant trade secrets matters around the world and who handled them.   18 August 2025
Americas
A pair of patents behind an infringement case that proved expensive for Amgen have been found “unenforceable due to inequitable conduct”.   15 August 2025
Careers
The pair follow heads of tech and litigation out the door, bringing experience of representing clients before district courts, Federal Circuit, PTAB, and the ITC.   14 August 2025
Americas
A procedural change at the Patent Trial and Appeal Board offers petitioners a valuable tool to push back against Fintiv-based discretionary denial, writes Taylor Stemler of Merchant & Gould.   14 August 2025